Literature DB >> 29146499

Antimicrobial resistance and virulence genes profiling of methicillin-resistant Staphylococcus aureus isolates in a burn center: A 5-year study.

Bei Jiang1, Supeng Yin1, Bo You1, Yali Gong1, Guangtao Huang1, Zichen Yang1, Yulong Zhang1, Yu Chen1, Jing Chen1, Zhiqiang Yuan1, Xiaomei Hu2, Yizhi Peng3.   

Abstract

Methicillin-resistant S. aureus (MRSA) has attracted more and more attention in recent years, especially in burn medical centers. Here we conducted a 5-year period study to evaluate the MRSA infection in our burn center. The staphylococcal chromosomal cassette mec (SCCmec) typing, antimicrobials susceptibility and virulence profiles were also performed among the MRSA isolates. Of the 259 S. aureus isolates, 239 (92.28%) isolates were identified as MRSA. A decreased trend of MRSA isolation rate over time was found (P = 0.0063). Majority of MRSA isolates in our center belonged to SCCmec type III (230/239, 96.23%). Antimicrobials susceptibility tests of the MRSA isolates revealed significantly decreased resistance to clindamycin (P = 0.0183), and increased resistance to chloramphenicol (P = 0.0020) and minocycline (P < 0.0001) over time. Trimethoprim/sulfamethoxazole, clindamycin, vancomycin, teicoplanin and linezolid were suggested to be good choice for MRSA infection in our center. Virulence factors profiling showed that most of MRSA isolates in our center carried the virulence factor pattern of cna-clfA-clfB-eno-fib-icaA-icaD-sea-psmα-lukED-hlg-hlgv-hla-hld (214/239, 89.54%). In conclusion, our study suggests that MRSA infection is serious in our burn center, but presented decreased trend over time. Most of MRSA isolates in our center presented the same virulence factor profile. More attention should be attached to nosocomial infection in burn medical center. Antimicrobials susceptibility changing over time was observed. Antimicrobials susceptibility monitoring is necessary and helps to select appropriate drugs against MRSA infections.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Antimicrobials susceptibility; Burn; MRSA; SCCmec type III; Virulence factor

Mesh:

Substances:

Year:  2017        PMID: 29146499     DOI: 10.1016/j.micpath.2017.11.020

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

1. 

Authors:  A Krir; S Dhraief; A A Messadi; L Thabet
Journal:  Ann Burns Fire Disasters       Date:  2019-09-30

2.  Prevalence of MRSA as an Infectious Agent in Sanitary Swimming Pools and Jacuzzis.

Authors:  Fatemeh Khamesi; Mohammad Hasan Ehrampoush; Vali Dad; Sara Jambarsang; Mohammad Taghi Ghaneian
Journal:  J Environ Health Sci Eng       Date:  2022-01-08

3.  Photothermal inactivation of methicillin-resistant Staphylococcus aureus: anti-biofilm mediated by a polypyrrole-carbon nanocomposite.

Authors:  Niloufar Behzadpour; Neda Akbari; Naghmeh Sattarahmady
Journal:  IET Nanobiotechnol       Date:  2019-10       Impact factor: 1.847

4.  Antimicrobial resistance, virulence genes profiling and molecular relatedness of methicillin-resistant Staphylococcus aureus strains isolated from hospitalized patients in Guangdong Province, China.

Authors:  Yingjian Liang; Changli Tu; Cuiyan Tan; Mohamed Abd El-Gawad El-Sayed Ahmed; Min Dai; Yong Xia; Yan Liu; Lan-Lan Zhong; Cong Shen; Guanping Chen; Guo-Bao Tian; Jing Liu; Xiaobin Zheng
Journal:  Infect Drug Resist       Date:  2019-02-25       Impact factor: 4.003

5.  Eleutheroside K Isolated from Acanthopanax henryi (Oliv.) Harms Inhibits the Expression of Virulence-Related Exoproteins in Methicillin-Resistant Staphylococcus aureus.

Authors:  Qian-Qian Li; Jiao Luo; Xiang-Qian Liu; Ok-Hwa Kang; Dong-Yeul Kwon
Journal:  Curr Microbiol       Date:  2021-09-23       Impact factor: 2.188

6.  Molecular characteristics and virulence gene profiles of Staphylococcus aureus causing bloodstream infection.

Authors:  Xuehan Li; Fang Fang; Jin Zhao; Ning Lou; Chenglin Li; Tao Huang; Yirong Li
Journal:  Braz J Infect Dis       Date:  2018-12-27       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.